Cetrelimab, CAS 2050478-92-5

Product Description: Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89(4):515-527.

CAS Number: 2050478-92-5

Molecular Weight: N/A

Compound Purity: 99.0

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Interleukin Related;PD-1/PD-L1;TNF Receptor

• Artikelnummer: MEXHY-P99499-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99499-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated